U.S. Therapeutic Drug Monitoring (TDM) Market for 28 Assays, 2020 Report - Supplier Shares & Strategies, Volume and Sales Segment Forecasts - ResearchAndMarkets.com

The "2020 US Therapeutic Drug Monitoring (TDM) Market for 28 Assays: Supplier Shares and Strategies, Volume and Sales Segment Forecasts" report has been added to ResearchAndMarkets.com's offering.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, April 29, 2020
Information
Tags: 
Biotechnology, Pharmaceutical, Health, Drugs, Chemistry, Amides, Immunosuppressants, Macrolides, RTT, Aminoglycoside antibiotics, Polyenes, Everolimus, Therapeutic drug monitoring, Levetiracetam, Procainamide
⚠generated by AI ↴
Summary
Key Points: 
  • The "2020 US Therapeutic Drug Monitoring (TDM) Market for 28 Assays: Supplier Shares and Strategies, Volume and Sales Segment Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • This 249-page report provides a comprehensive analysis of the US therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers.
  • The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid and Vancomycin.
  • The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors.


The "2020 US Therapeutic Drug Monitoring (TDM) Market for 28 Assays: Supplier Shares and Strategies, Volume and Sales Segment Forecasts" report has been added to ResearchAndMarkets.com's offering.

This 249-page report provides a comprehensive analysis of the US therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers.

The report provides test volume and sales forecasts by country and market segment for the following assays: Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid and Vancomycin.

During the next five years, the TDM market will undergo significant transformation. These changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others.

This report is a unique market and technology assessment designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses. The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors.

Companies Mentioned

  • Abbott Laboratories
  • Agilent Technologies
  • Beckman Coulter/Danaher
  • bioMerieux
  • Bio-Rad
  • DiaSorin
  • Eiken Chemical
  • Fujirebio
  • Grifols
  • Instrumentation Laboratory/Werfen
  • Kyowa Medex
  • Ortho-Clinical Diagnostics
  • PerkinElmer
  • Quest Diagnostics
  • Roche
  • Siemens Healthineers
  • Sysmex
  • Thermo Fisher
  • Tosoh
  • Wako

For more information about this report visit https://www.researchandmarkets.com/r/z2q5km

Copyright: 
Copyright Business Wire 2020